Effectiveness of a Grape Seed Extract on Circulatory Measures in Healthy Adults

Last updated: November 16, 2025
Sponsor: RDC Clinical Pty Ltd
Overall Status: Active - Not Recruiting

Phase

3

Condition

N/A

Treatment

Maltodextrin

Grape Seed Extract

Clinical Study ID

NCT06440252
ALVCIR
  • Ages > 25
  • All Genders

Study Summary

This is a randomized, double-blind, placebo-controlled, 2 arm crossover study conducted over 11 weeks, with participants randomised to a product for 4 weeks, followed by a 3-week washout period before completing the second product for 4 weeks, to study the effectiveness of a grape seed extract on circulatory measures in healthy adults.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Adults 25 years or older

  • Generally healthy

  • BMI 18 - 35kg/m2

  • Able to provide informed consent

  • Have prehypertensive blood pressure (systolic 120-139 mmHg and/or diastolic 80-89mmHg)

  • Agree to not change current diet and/or exercise frequency or intensity duringentire study period

  • Agree to not participate in another clinical trial while enrolled in this trial

Exclusion

Exclusion Criteria:

  • Those with a history of myocardial infarction, angina or bleeding disorders

  • Those who have uncontrolled thyroid diseases

  • Currently taking dietary supplements for circulation (e.g. fatty acids, CoQ10,L-arginine, red ginseng, ginseng, natto, ginkgo) or use of these in the last 1 month

  • Currently taking inflammation or circulatory associated medications (e.g.Pentoxifylline and vasodilators like nitroglycerin) or use of these in the last 1month

  • Currently taking statins medication including atorvastatin (e.g. Lipitor, Lorstat),fluvastatin (e.g. Lescol or Vastin), pravastatin (e.g. Pravachol, Cholstat),rosuvastatin (e.g. Cavstat, Crestor) or simvastatin (e,g, Lipex, Zocor, Zimstat).

  • Currently taking Coumadin, Marevan (Warfarin), Heparin, Dalteparin, Enoxaparin orother anticoagulation therapy, or substrates of P-glycoprotein including (but notlimited to) calcium channel blockers, cyclosporin, digoxin, erythromycin andprotease inhibitors(1).

  • Have a serious illness(2) e.g. mood disorders such as bipolar disorder, neurologicaldisorders such as MS, kidney disease, liver disease or heart conditions

  • Have an unstable illness(3) (i.e., changing medication/treatment)

  • Malignancy or treatment for malignancy within the previous 2 years (this excludesnon-melanoma (e.g. BCC and SCC) skin cancers not requiring radiation orchemotherapy)

  • Active smokers, nicotine use or drug (prescription or illegal substances) abuse

  • Chronic past and/or current alcohol use (>14 alcoholic drinks week)

  • Allergic to any of the ingredients in active or placebo formula

  • Pregnant or lactating woman or women trying to conceive

  • Any condition which in the opinion of the investigator makes the participantunsuitable for inclusion

  • Participated in another trial in the past 1 month

  1. Any participant that begins taking antiplatelet medication during the trialwill be excluded from the study

  2. A serious illness is a condition that carries a risk of mortality, negativelyimpacts quality of life and daily function and/or is burdensome in symptomsand/or treatments.

  3. An unstable illness is any illness that is currently not being treated with astable dose of medication or is fluctuating in severity.

Study Design

Total Participants: 150
Treatment Group(s): 2
Primary Treatment: Maltodextrin
Phase: 3
Study Start date:
October 31, 2024
Estimated Completion Date:
December 31, 2025

Connect with a study center

  • RDC Clinical Pty Ltd

    Brisbane, Queensland 4006
    Australia

    Site Not Available

  • RDC Clinical Pty Ltd

    Brisbane 2174003, Queensland 2152274 4006
    Australia

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.